Product Pipeline Analysis of Accugenomics Inc – 2019 Update – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Accugenomics Inc – Product Pipeline Analysis, 2019 Update” company profile has been added to ResearchAndMarkets.com’s offering.


Accugenomics Inc (Accugenomics) is a developer of oncology molecular diagnostics. The company develops and markets gene expression tests to diagnose and monitor cancer treatment. It offers gene expression tests including lung cancer risk test, standardized BCR-ABL molecular diagnostics test and lung cancer diagnostic test. Accugenomics’ product candidates comprises of LCDT-AGx-3 Gene lung cancer diagnostic tests that helps in improving diagnostic precision as an adjunct to morphological criteria; and LCCT-AGx-4 Gene lung cancer chemoresistance test to estimate the response of different lung cancers to cisplatin or irinotecan related treatments. The company operates through its development laboratory in Wilmington, North Carolina. Accugenomics is headquartered in Wilmington, North Carolina, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Accugenomics Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Key Topics Covered:

  • Accugenomics Inc Company Overview
  • Accugenomics Inc Company Snapshot
  • Accugenomics Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Accugenomics Inc – Pipeline Analysis Overview
  • Accugenomics Inc – Key Facts
  • Accugenomics Inc – Major Products and Services
  • Accugenomics Inc Pipeline Products by Development Stage
  • Accugenomics Inc Ongoing Clinical Trials by Trial Status
  • Accugenomics Inc Pipeline Products Overview
  • AccuKit
  • AccuKit Product Overview
  • Lung Cancer Chemoresistance Test – 4 Gene
  • Lung Cancer Chemoresistance Test – 4 Gene Product Overview
  • Lung Cancer Diagnostic Test – 3 Gene
  • Lung Cancer Diagnostic Test – 3 Gene Product Overview
  • Lung Cancer Risk Test – 13 Gene
  • Lung Cancer Risk Test – 13 Gene Product Overview
  • Lung Cancer Risk Test – 15 Gene
  • Lung Cancer Risk Test – 15 Gene Product Overview
  • Lung Cancer Risk Test – 15 Gene Clinical Trial
  • Accugenomics Inc – Key Competitors
  • Accugenomics Inc – Key Employees
  • Accugenomics Inc – Locations And Subsidiaries
  • Head Office
  • Recent Developments
  • Accugenomics Inc, Recent Developments
  • May 21, 2019: Precision Therapeutics’ Helomics division selected by AccuGenomics as preferred lab partner for NIIMBL grant
  • Aug 15, 2017: AccuGenomics Provides an AccuKit to Qura Therapeutics as Part of a Research Collaboration Agreement
  • Aug 15, 2017: AccuGenomics Provides an AccuKit to Qura Therapeutics as Part of a Research Collaboration Agreement
  • Jul 08, 2016: AccuGenomics presents their molecular standardization technology at GTCbio Molecular Diagnostic Conference in Boston, MA.
  • Jan 29, 2016: Release of lung cancer risk test trial details and establishment of biospecimen repository
  • Dec 18, 2015: Progress in Efforts to Develop AccuKit for Monitoring of BCR-ABL Treatment
  • Jul 01, 2015: STARSEQ Demonstrates Measurement of Undetected Errors that Arise in Next Generation Sequencing
  • Jun 11, 2015: SNAQ BCR-ABL Pilot Study Results Presented at 20th Annual European Hematology Association Meeting
  • Sep 07, 2014: Preliminary SNAQ BCR-ABL Pilot results presented at the 16th Annual John Goldman Conference on Chronic Myeloid Leukemia
  • Jul 01, 2014: AccuGenomics awarded United States patent for a molecular test that predicts lung cancer risk
  • Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer

Companies Mentioned

  • Orion Genomics LLC
  • IV Diagnostics Inc
  • 20/20 GeneSystems Inc
  • Lincoln Diagnostics Inc
  • DermTech Inc
  • AlphaGenics Inc
  • Co-Diagnostics Inc

For more information about this company profile visit https://www.researchandmarkets.com/r/3i6g57



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.